Published in
Korean Cancer Association, Cancer Research and Treatment, 3(49), p. 834-845, 2017
DOI: 10.4143/crt.2016.249
Links
- ORCID
- ORCID
- ORCID
- ORCID
- Korean Cancer Association | PDF
- [hdl.handle.net]
- [hdl.handle.net]
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
Tools
Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
Journal article published in 2016 by
Chiara Cremolini 
,
Filippo de Braud,
Carlotta Antoniotti,
Filippo Pietrantonio,
Rosa Berenato,
Marco Tampellini,
Chiara Baratelli,
Lisa Salvatore ,
Federica Marmorino,
Beatrice Borelli,
Federico Nichetti,
Paolo Bironzo ,
Cristina Sonetto,
Maria Di Bartolomeo ,
Filippo de Braud
and other authors.
,
Filippo de Braud,
Carlotta Antoniotti,
Filippo Pietrantonio,
Rosa Berenato,
Marco Tampellini,
Chiara Baratelli,
Lisa Salvatore ,
Federica Marmorino,
Beatrice Borelli,
Federico Nichetti,
Paolo Bironzo ,
Cristina Sonetto,
Maria Di Bartolomeo ,
Filippo de Braud
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 
Abstract
To evaluate progression-free survival (PFS) and objective response rate (ORR) as surrogate endpoints of overall survival (OS) in modern clinical trials investigating the efficacy of targeted agents in the second-line treatment of metastatic colorectal cancer (mCRC).